Agios Medical Booth

American Society of Clinical Oncology Annual Meeting 2020

IDH Mutations in Cancer

At Agios, our lead oncology programs are focused on cancers with a mutated isocitrate dehydrogenase (IDH) protein. IDH mutations occur in a wide range of blood and solid tumor cancers, including acute myeloid leukemia (AML), cholangiocarcinoma and glioma. Normally, IDH enzymes help to break down nutrients and generate energy for cells. When mutated, IDH creates a molecule that alters the cells’ genetic programming, and instead of maturing, the cells remain primitive and proliferate quickly. Agios believes that targeting mutated IDH may have the potential to benefit the subset of patients with tumors that carry IDH mutations.

IDH Inhibition Mechanism of Action

IDH Mutation Testing

Explore the role of IDH mutations in mIDH-positive cancers and the importance of molecular profiling.

Learn More

 

Find out more about IDH mutations in hematologic malignancies and solid tumors.

ExploreIDH.com

Ongoing Clinical Trials

Patient Resources

Contact Us

Medical Information Inquiries
  • Agios Medical Information Call Center
  • Monday – Friday 7:00am – 6:00pm CT
  • with Urgent After Hours

IVO-US-0504